美国食品和药物管理局批准首次FSGS治疗8岁以上无综合征的患者. FDA approves first FSGS treatment for patients 8+ without nephrotic syndrome.

对于没有脏综合征的8岁及以上患者,Filspari (sparsentan) 是第一种也是唯一一种用于焦点细分结核硬化症 (FSGS) 的治疗方法. Travere Therapeutics has received FDA approval for Filspari (sparsentan), the first and only treatment for focal segmental glomerulosclerosis (FSGS) in patients aged eight and older without nephrotic syndrome. 经过成功的临床试验,该药物显著减少蛋白尿并改善功能. This approval follows successful clinical trials showing the drug significantly reduces proteinuria and improves kidney function. 阻断特定受体的Filspari也用于治疗IgA腎病,为患有这些罕见疾病的患者提供了新的选择. Filspari, which blocks specific kidney receptors, is also used to treat IgA nephropathy, offering new options for patients with these rare kidney diseases.